Scancell Holdings PLC

Scancell chief hints at future Nasdaq listing

Richard Goodfellow, chief executive of Scancell (LON:SCLP), says the immuno-oncology specialist could explore the option of a NASDAQ listing once it has built up its North American profile.

The CEO was speaking to Proactive following the announcement of two new appointments - Dr John Chiplin, who will join the board as a non-executive director, and Dr Peter Brown, who is to be an advisor to the drug developer.

The former brings with him a wealth of industry experience, having been instrumental in the NASDAQ listing of Australia-quoted Benitec Biopharma.

Scancell’s first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials.

Quick facts: Scancell Holdings PLC

Price: £0.07

Market: LSE
Market Cap: £32.81 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...


2 min read